SCHEMBL913428

SCHEMBL913428

COc1cccc(-c2nc3cc(Cl)ccc3c(=O)o2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.73
HPGD P15428 4/20 0.73
KMT2A Q03164 2/20 0.73
F2 P00734 1/20 0.73
MAPT P10636 6/20 0.64
HSD17B10 Q99714 2/20 0.64
ELANE P08246 1/20 0.62
KDM4E B2RXH2 5/20 0.58
SMN1; SMN2 Q16637 4/20 0.56
TP53 P04637 3/20 0.56
LMNA P02545 3/20 0.55
MAOB P27338 1/20 0.54
MEN1 O00255 1/20 0.54
NPC1 O15118 4/20 0.53
RAB9A P51151 3/20 0.53
APEX1 P27695 1/20 0.53
NOTUM Q6P988 1/20 0.51
GLA P06280 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14417719 0.89 ALDH1A1 (0.66) ALDH1A1HPGDKMT2AF2MAPT
SCHEMBL5772611 0.85 ALDH1A1 (1.00) ALDH1A1HPGDKMT2AF2MAPT
SCHEMBL916042 0.84 PBRM1 (0.63) ALDH1A1HPGDKMT2AF2MAPT
SCHEMBL6565952 0.82 APEX1 (0.59) ALDH1A1HPGDKMT2AF2MAPT
SCHEMBL914144 0.81 APEX1 (0.56) ALDH1A1HPGDKMT2AF2MAPT
SCHEMBL1463884 0.81 ALDH1A1 (0.75) ALDH1A1HPGDKMT2AF2MAPT
SCHEMBL6567250 0.80 APEX1 (0.63) ALDH1A1HPGDKMT2AMAPTELANE
SCHEMBL914070 0.79 APEX1 (0.54) ALDH1A1HPGDKMT2AF2MAPT
SCHEMBL14417720 0.79 ALDH1A1 (0.66) ALDH1A1HPGDKMT2AF2MAPT
SCHEMBL14273715 0.78 KDM4E (0.58) ALDH1A1HPGDKMT2AF2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872052-B2 Use of heterocyclic compounds as SCCE inhibitors AREXIS AB (SE) 2011-01-18 US disclosed
US-20060258651-A1 Use of heterocyclic compounds as scce inhibitors QUANTUM LTO HOLDINGS, LLC 2006-11-16 US disclosed
EP-1631295-A2 USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER Arexis AB (SE) 2006-03-08 EP disclosed
WO-2004108139-A2 USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER AREXIS AB (SE) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258651-A1 Use of heterocyclic compounds as scce inhibitors RCE1, CTSE, SPINT2 ALDH1A1 584/4885HPGD 73/4885KMT2A 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.